MarketInOut Stock Screener Log In | Sign Up
 

Lexaria Bioscience Corp

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Lexaria Bioscience Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6.49 mln
Float2.04 mln
Earnings Date10/13/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-3.61
Highly reliable

1-Year Forecast

82.50
Transformational upside

Relative Strength

30 / 100
Underperforming

Debt / Equity

0.02
Debt-free

Pre-Tax Margin

-3,988%
Severely loss-making

Business Description

Lexaria Bioscience Corp. is a Canadian biotechnology company built around its patented DehydraTECH delivery platform, which uses fatty acid-rich oils to help active ingredients absorb into the bloodstream more efficiently. This improved absorption means medications and other compounds can work better at lower doses, making them easier to tolerate. The technology works across a broad range of substances ? from diabetes and weight-loss drugs to vitamins, hormones, and cannabinoids ? and can be applied to everyday product formats such as tablets, capsules, beverages, and foods.

Key Fundamentals

EPS-5.10
ROE-156
RPS0.13
ROIC-833
ROA-137
EBITDA, mln-7.64
EV / EBITDA-0.27
EV / EBIT-0.27
Revenue, mln0.19
EV / Revenue10.74

Quote Details

Last 3.08
Change 0.09 (3.01%)
Open 2.98
Volume 23,226
Turnover 71,536
Average Volume 61,970

Financial Ratios

Pre-Tax Profit Margin-3,988
Leverage Ratio1.01
Current Ratio10.60
Price / Book0.99
Price / Tangible Book1.07
Debt / Equity0.02
Price / Sales19.62

Financial Strength

Altman Z-Score-16.28
Piotroski F-Score 3 / 9
Beneish M-Score-3.61
1-Year Target Price82.50
Short Ratio2.68
Short % of Float13.43

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 7.69% 92 / 100   
1 Month -8.61% 32 / 100   
2 Months -65.78% 4 / 100   
6 Months -78.25% 5 / 100   
1 Year -77.57% 9 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog